The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 18, 2025

Filed:

Oct. 04, 2023
Applicant:

Cellectis, Paris, FR;

Inventors:

Laurent Poirot, Paris, FR;

David Sourdive, Levallois-Perret, FR;

Philippe Duchateau, Dravell, FR;

Jean-Pierre Cabaniols, Saint Lau la Foret, FR;

Assignee:

CELLECTIS, Paris, FR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/85 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C12N 5/0783 (2010.01); C12N 15/113 (2010.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 15/85 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 14/70503 (2013.01); C07K 14/70539 (2013.01); C12N 5/0636 (2013.01); C12N 15/1138 (2013.01); C12N 15/907 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01);
Abstract

The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and/or CIITA, or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component.


Find Patent Forward Citations

Loading…